carvedilol studies
Select the study ID number to view the trial summary
| Study ID | Phase | Title |
| 346/347 (GEMINI) | IV | A Randomized, Double-Blind, Multicenter Study Comparing the Glycemic Control Characteristics of Carvedilol and Metoprolol in Hypertensive Patients with Type II Diabetes Mellitus (Protocol 346) and A Randomized, Double-Blind, Multicenter Study Comparing the Effects of Carvedilol and Metoprolol on Glycemic Control in Hypertensive Patients with Type II Diabetes Mellitus (Protocol 347) |
| WE175 | IV | Differential association of beta-blockers with hemorrhagic events for chronic heart failure patients on warfarin |
| 220 | III | A six-month, double-blind, placebo-controlled, multicenter dose-ranging comparison of oral carvedilol b.i.d. in patients with congestive heart failure, NYHA Class II-IV. |
| 221 | III | A six-month, double-blind, multicenter comparison of oral carvedilol b.i.d. with placebo in patients with congestive heart failure, NYHA Class II-IV. |
| 223 | III | A randomized trial of carvedilol (a beta-adrenergic antagonist with vasodilator properties) in patients with ischemic congestive cardiomyopathy. |
| 239 | III | A six-month, double-blind, multicenter comparison of oral carvedilol b.i.d. with placebo in patients with severe congestive heart failure, NYHA Class III-IV. |
| 240 | III | A twelve-month double-blind multicenter comparison of oral carvedilol b.i.d. with placebo in patients with mild congestive heart failure, NYHA Class II-III. |
| 269 | III | A multi-national, multi-centre, randomized, double-blind, parallel-group study to determine the effects of carvedilol on mortality and morbidity in patients with left ventricular dysfunction, with or without clinical evidence of heart failure, post myocardial infarction. |
| 028 (B104) | III | Placebo controlled assessment of carvedilol (SK&F 105517) and labetalol in black patients with mild to moderate hypertension |
| 092-C1106 | III | A multicenter, double-blind, placebo-controlled, randomized assessment of carvedilol (SK&F 105517) administered once (UID) or twice (BID) daily to patients with mild to moderate hypertension. |
| 095-C1109 | III | Carvedilol (SK&F 105517) versus atenolol and placebo in patients with mild to moderate essential hypertension. |
| 287-COPERNICUS | III | Carvedilol Prospective Randomized Cumulative Survival Trial. |
| C1702 | III | A multicenter, double-blind, crossover study of three doses of carvedilol compared to placebo in patients with exertional angina. |
| C1703 | III | A multicenter, double-blind, crossover study of carvedilol compared to placebo in patients with exertional angina. |
| CAR-IT-01 (IT-88-CAR-01) | III | A pilot study on the efficacy and the safety of carvedilol in the elderly. |
| CAR-UK-104 | III | A multicentre study of efficacy and safety of carvedilol in the elderly. |
| COR103560 | III | A Randomized, Double-blind, Positive-Controlled, Multicenter Study Comparing the Efficacy of Carvedilol Phosphate Modified Release Formulation (COREG MR) and Metoprolol Succinate Extended Release (Toprol-XL®) on the Reduction of Microalbuminuria in Patients with Hypertension and Microalbuminuria. |
| INT-CAR-06 | III | Carvedilol-nifedipine S.R. interaction study. |
| INT-CAR-07 | III | Comparison of carvedilol to atenolol in the treatment of mild to moderate essential hypertension. |
| INT-CAR-10 | III | A comparison of the safety and efficacy of carvedilol with that of nifedipine s.r. in patients with mild to moderate benign essential hypertension |
| INT-CAR-11 | III | A comparison of carvedilol with hydrochlorothiazide in the treatment of mild to moderate benign essential hypertension. |
| INT-CAR-12 | III | Comparison of carvedilol to captopril in the treatment of mild to moderate hypertension. |
| INT-CAR-13 | III | Effect of carvedilol as compared to an ACE-inhibitor (enalapril) on hypertension and “quality of life” related well-being. |
| SK&F-105517/321 | III | A multicenter, placebo-controlled, 8-month study of the effect of twice daily carvedilol in children with congestive heart failure due to systemic ventricular systolic dysfunction |
| SK&F-105517/367 | III | A Randomized, Double-Blind, Multicenter Study Comparing the Effects of Administration of Modified Release COREG or Placebo on Blood Pressure in Essential Hypertension Patients |
| SK&F-105517/396 | III | A multicenter, open-label extension study to evaluate the safety of twice daily oral carvedilol in pediatric subjects with chronic heart failure (including results of Study 321 Open Label phase [321OL]) |
| 093-C1107 | II | A multicenter, double-blind, placebo-controlled, randomized assessment of carvedilol (SK&F 105517) in patients whose blood pressure is uncontrolled on hydrochlorothiazide (HCTZ). |
| B100 | II | A multicenter, double-blind, placebo-controlled comparison of Carvedilol (SK&F) 6.25 mg, 12.5 mg, and 25.0 mg administered twice daily in patients with mild and moderate hypertension. |
| B101 | II | A multicenter, double-blind, placebo-controlled comparison of carvedilol (SK&F 105517) 6.25mg, 12.5mg, 25mg, and 50mg administered once daily in patients with mild to moderate hypertension. |
| B1103 | II | A study to investigate the effect of renal insufficiency on the pharmacokinetics of carvedilol and the metabolites of carvedilol after single and multiple dose administration in patients with hypertension. |
| INT-CAR-08 | II | Comparison of carvedilol to acebutolol in the treatment of mild to moderate benign essential hypertension. |
| 177 | I | A pharmacokinetic study of a single oral dose of carvedilol 25mg administered to healthy elderly males compared to the same dose given to healthy young males. |
| 233 | I | Single- and Multiple-Dose Pharmacokinetics of Carvedilol and Enantiomers of Carvedilol in Patients with Congestive Heart Failure Compared to Normal Volunteers. |
| 234 | I | A study to determine the effect of carvedilol on the anticoagulant effect of warfarin and on the pharmacokinetics of warfarin enantiomers. |
| 236 | I | Multiple dose Pharmacokinetics of Carvedilol and its Enantiomers in Patients with Congestive Heart Failure. |
| A0003 | I | Effect of carvedilol, administered orally at doses of 12.5, 25.0 and 50.0mg, on renal function in healthy subjects. |
| A0004 | I | Effect of chronic administration of carvedilol, 6.25mg to 25mg b.i.d., on renal hemodynamics in mild to moderate essential hypertension. |
| A9901 | I | A pharmacokinetic study of carvedilol, 25 mg orally (SK&F 105517) to study the intra-subject variability and stereoselectivity of the pharmacokinetics in healthy subjects. |
| A9903-US | I | A dose proportionality study of carvedilol enantiomers following doses of racemic carvedilol (SK&F 105517 – capsules) of 6.25, 12.5, 25.0 and 37.5mg orally in healthy subjects. |
| A9904-GER | I | A study to assess the acute effects of the co-administration of a single dose of 25mg carvedilol (SK&F 105517) on the plasma and urinary pharmacokinetics of digoxin after administration of a single dose of 0.5mg digoxin in normal man. |
| A9905-GER | I | A study to assess the acute effects of the co-administration of a single dose of 25mg carvedilol (SK&F 105517) on the plasma and urinary pharmacokinetics of digoxin after administration of a single intravenous dose of 0.5mg digoxin in normal man. |
| A9907 | I | A study to assess the acute effects of a standard meal on the pharmacokinetics of carvedilol, after administration of a single oral dose of 25mg carvedilol in normal man. |
| A9911-US | I | A study to investigate the pharmacokinetics of carvedilol enantiomers and the metabolites of carvedilol in poor and extensive metabolizers of debrisoquin. |
| B1102 | I | A crossover study to compare the effect of carvedilol (SK&F 105517) and atenolol administered orally on renal hemodynamics in patients with mild to moderate essential hypertension. |
| CAR 8902 | I | Report of a study to assess the effects of inhibition and induction of hepatic mixed function oxidase activity on the pharmacokinetics of a single oral dose of carvedilol in 8 healthy volunteers. |
| CAR-UK-105 | I | A double-blind, placebo controlled study of the acute effect of carvedilol and atenolol in patients uncontrolled on bendrofluazide. |
| CARV0002 | I | A Study of the Pharmacodynamics and Pharmacokinetics of Intravenous Carvedilol in Normal Volunteers. |
| CFD 105533 | I | A randomized, open-label, single-dose, four-period cross-over study to evaluate the relative bioavailability of four formulations of GSK lisinopril compared to Zestril, and to compare over-encapsulated Zestril to Zestril |
| CRV 106904 | I | A Randomized, Open-Label, Single-Dose, Four-Period Cross-Over Study to Determine the Effects of Alcohol on the Pharmacokinetics of Carvedilol CR |
| CRV104257 | I | A randomized, open-label, two period, period balanced, crossover study to estimate the relative bioavailability of an investigational drug compared to Coreg IR in healthy adult volunteers |
| INT-CAR-05 | I | Carvedilol – captopril interaction study. |
| INT-CAR-30A | I | The effect of oral carvedilol 6.25mg, 12.5mg, 25mg and 50mg on exercise-induced tachycardia and blood pressure in healthy volunteers. |
| INT-CAR-30B | I | Determination of alpha and beta blockade thresholds for carvedilol in comparison to 400mg labetalol in healthy volunteers. |
| SK&F-105517/902 | I | A Randomized, Double-Blind, Placebo-Controlled, PK/PD Modeling, Multicenter Study to Compare the B1-Blocking Effects of an investigational formulation of carvedilol to COREG® Immediate Release Tablets at Steady-State in Adult Patients with Essential Hypertension, by Evaluating Heart Rate Response to Bicycle Ergometry |
| SK&F-105517/906 | I | An Open-label, Single Dose, Three Session, Partially Randomized, Crossover Study to Assess Morning and Evening Dosing of Carvedilol Phosphate MR Capsules in Healthy Adult Subjects |
| SK&F-105517/908 | I | A randomized, single-blind, placebo-controlled, three-period parallel-group study to assess the pharmacokinetic and pharmacodynamic relationship of a 50 mg single oral dose of immediate release carvedilol in healthy subjects |